tbuckley/cabot-search huggingface dataset:
A CASE OF THE SENEAR-USHER SYNDROME TREATED WITH ACTH AND CORTISONE
Authors: S L SWILLER, H GOLD
Journal: Annals of Internal Medicine (1953)

Case Reports1 December 1953A CASE OF THE SENEAR-USHER SYNDROME TREATED WITH ACTH AND CORTISONESAMUEL L. SWILLER, M.D., HYMAN GOLD, M.D.SAMUEL L. SWILLER, M.D.Search for more papers by this author, HYMAN GOLD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-39-6-1323 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptINTRODUCTIONIn 1926 Senear and Usher1described "An Unusual Type of Pemphigus, Combining Features of Lupus Erythematosus." They presented four cases and reviewed seven others from the Transactions of several dermatologic societies. In essence, these were patients with lesions on the face that resembled lupus erythematosus and with lesions on the trunk that resembled pemphigus. Furthermore, it appeared that patients with this combined dermatitis had a prognosis considerably better than patients with either pemphigus or lupus. If nothing else, this fact singled out this syndrome as being of more than academic interest. Ormsby2suggested the name "pemphigus erythematodes." Since then...Bibliography1. SenearUsher FEB: An unusual type of pemphigus combining features of lupus erythematosus, Arch. Dermat. and Syph. 13: 761, 1926. CrossrefGoogle Scholar2. Ormsby OS: Diseases of the skin, 1943, Lea and Febiger, Philadelphia, p. 413. Google Scholar3. WileArnold UJHL: Senear-Usher syndrome: review of literature and report of six cases, Arch. Dermat. and Syph. 40: 687, 1939. CrossrefGoogle Scholar4. Wise , quoted in Sutton, R. L., and Sutton, R. L., Jr.: Handbook of diseases of the skin, 1949, C. V. Mosby Company, St. Louis. Google Scholar5. Zakon SJ: Naevo-epithelioma adenoides (cylindroma) of scalp, Arch. Dermat. and Syph. 40: 945, 1939. CrossrefGoogle Scholar6. Rattner H: Pemphigus: a bullous disease, M. Clin. North America 33: 165, 1949. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: *Received for publication May 19, 1953.From the Medical Services of the Maimonides Hospital, Brooklyn, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 December 1953Volume 39, Issue 6Page: 1323-1326KeywordsAdrenocorticotropic hormoneLesionsLupus erythematosusMedical servicesMemory ePublished: 1 December 2008 Issue Published: 1 December 1953 PDF downloadLoading ...
Heart Attack Triage
Authors: Joan Stephenson
Journal: JAMA (1999)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Current Medical Literature
Authors: Z Walker, R Butler, C Holmes
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Israeli doctors may now use cadavers for training purposes
Authors: J. Siegel-Itzkovich
Journal: BMJ (2001)

A new amendment to Israel's 1954 anatomy and pathology law now allows doctors to practise medical procedures on cadavers if the deceased person granted written permission in advance or the family consented after the person's death.

New rules have been issued by the health ministry's director general, Dr Boaz Lev. In addition to this written permission, three physicians must sign a document stating that the procedure was aimed at treating patients, and only procedures on a specified list are permitted.

In addition, if organs for transplant are to be taken from the cadaver, medical procedures for training doctors may not be performed if this will jeopardise the organ donation.

Moreover, medical procedures will not be allowed on …
Management of anaphylaxis in primary care: Canadian expert consensus recommendations
Authors: S. Waserman, Z. Chad, M. J. Francoeur, P. Small, D. Stark, T. K. Vander Leek, A. Kaplan, M. Kastner
Journal: Allergy (2010)

Anaphylaxis is often managed inadequately. We used findings from a systematic review of gaps in anaphylaxis management to develop evidence-based recommendations for gaps rated as clinically important by a panel of Canadian allergy experts.The nominal group technique (NGT) consensus methodology was used to develop evidence-based recommendations for the management of anaphylaxis in primary care. Physician-specific gaps from our systematic review were prioritized by consensus meeting participants in two rounds, which involved the rating, discussion, and re-rating of gaps. Using current anaphylaxis guidelines, recommendations were then developed for each category of gaps that were identified by the panel as clinically important.Thirty unique physician gaps from the systematic review were categorized according to gaps of knowledge and anaphylaxis practice behaviors. The panel rated diagnosis of anaphylaxis, and when and how to use epinephrine auto-injectors as clinically important knowledge gaps; and rated infrequent or delayed epinephrine administration, low rate of auto-injector prescription, and infrequent or no referrals to allergy specialists after a reaction as important practice behavior gaps. Evidence from four guidelines was used to support the consensus recommendation statements for three resulting categories of gap themes: anaphylaxis management, epinephrine use, and follow-up care.We used an NGT consensus methodology to develop an educational resource for primary care physicians and allergists to better understand how to manage patients with anaphylaxis. Next steps include testing our findings against observed data in primary care settings and to develop other strategies or tools to overcome gaps in anaphylaxis management.
ERRORS IN THE CLINICAL APPLICATION OF ELECTROCARDIOGRAPHY
Authors: William B. Breed, James M. Faulkner
Journal: Annals of Internal Medicine (1936)

Article1 July 1936ERRORS IN THE CLINICAL APPLICATION OF ELECTROCARDIOGRAPHYWILLIAM B. BREED, M.D., F.A.C.P., JAMES M. FAULKNER, M.D., F.A.C.P.WILLIAM B. BREED, M.D., F.A.C.P.Search for more papers by this author, JAMES M. FAULKNER, M.D., F.A.C.P.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-10-1-58 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptThe last twenty years have seen an enormous growth in the use of the electrocardiograph as a diagnostic instrument. From a cumbersome and expensive machine available only to the larger hospitals and clinics have been developed models which are light enough and cheap enough to be entirely practicable for use in office or home. It is estimated that there are three thousand electrocardiographs in active use in this country today and the number of instruments is rapidly increasing. A result of this tremendous growth has been that we as internists are being called upon more and more to assess the...References1. WILSON FN: A case in which the vagus influenced the form of the ventricular complex of the electrocardiogram, Arch. Int. Med., 1915, xvi, 1008. CrossrefGoogle Scholar2. WOLFFPARKINSONWHITE LJPD: Bundle branch block with short P-R interval in healthy young people prone to paroxysmal tachycardia, Am. Heart Jr., 1930, v, 685. CrossrefGoogle Scholar3. GRAYBIELWHITE APD: Inversion of the T-wave in Lead I or II of the electrocardiogram in young individuals with neurocirculatory asthenia, with thyrotoxicosis in relation to certain infections, and following paroxysmal tachycardia, Am. Heart Jr., 1935, x, 345. CrossrefGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Boston, Massachusetts*Presented at the Detroit meeting of the American College of Physicians, March 3, 1936. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited by�ber tagesrhythmische Schwankungen im Elektrokardiogramm (EKG) vegetativ Labiler und ihre Beeinflussung durch NahrungsaufnahmeKasuistikÜber die Entstehung des HerzinfarktsGrenzen der klinischen Elektrokardiographie 1 July 1936Volume 10, Issue 1Page: 58-64KeywordsElectrocardiographyHospitals ePublished: 1 December 2008 Issue Published: 1 July 1936 PDF downloadLoading ...
Abstract 10841: Prosthesis-patient Mismatch Affects Long-term Survival After Aortic Valve Replacement
Authors: Juergen Ennker, Alexander Albert, Andreas Boening, Ina C Ennker, Ines Florath
Journal: Circulation (2010)

Introduction:  There is an ongoing discussion about the impact of prosthesis-patient mismatch (PPM) on long-term survival after aortic valve replacement. In most of the previous studies PPM was assessed by the mean effective orifice area (EOA) obtained from reference tables provided in literature (projected EOA).   Hypothesis:  We assessed the hypothesis that PPM effects long-term survival after aortic valve replacement.   Methods:  Before discharge the EOA was measured by transthoracic echocardiography in 1012 patients undergoing aortic valve replacement between 1996 and 2006. Mean age was 70±10 years. Follow-up was 99% complete with 6172 patient-years and mean time of 6.1 years. Cox-regression was used to estimate the impact of indexed EOA on survival. The optimal transformation of indexed EOA (linear or binary) was determined by the greatest drop in deviance (deviance of the model without indexed EOA – deviance with indexed EOA in several transformations).   Results:  Predictors of survival time were age, pulmonary hypertension, atrial fibrillation, ejection fraction  2 /m 2  was identified as a significant predictor of survival time (HR: 1.3, p-Value: 0.015, deviance drop: 5.9). The projected indexed EOA was not a significant predictor of survival time neither in linear (p=0.31) nor in binary transformation (p=0.24). The scatter plot in the Figure below shows the relationship between projected and measured EOA, e.g. in patients with a projected EOA determined by reference values from literature of 1.5 cm 2  the real measured EOA varied between 0.7 and 2.2 cm 2 .   Conclusions:  Long-term survival was impaired by prosthesis-patient mismatch assessed by postoperatively echocardiographic measured EOA .
The use of submaximal metabolic stress test derived end tidal CO2 may reflect pulmonary hypertension and need for further workup
Authors: Mary Lynn Zaremba, Kristin Elliott, Alicia Redford, Syed Ali, Nipurn Shah, Sridhar Reddy
Journal: European Respiratory Journal (2011)

There is considerable interest in identifying patients with pulmonary hypertension. In a small pulmonary practice we looked at the use of end tidal CO2 (ETCO2) derived from a quick submaximal stress test and its relevance to pulmonary arterial pressures. Submaximal stress testing is much easier for patients to perform and is being increasingly used in a small office setting. We looked at patients with drops in ETCO2 on exercise and echocardiographic parameters of pulmonary hypertension.

During submaximal metabolic stress testing using Shape non-invasive medical devise, breath by breath analysis of air flow, O2 consumption and CO2 production were measured. Patients n=25 with a drop in ETCO2 (n=11) during exercise were compared to patients with a rise in ETCO2 (n=14). Echocardiographic parameters were extracted and used for analysis.

In the group of patients with a drop in ETCO2 there was a significantly higher peak right ventricular systolic pressure (p=0.013477) compared to patients with an increase in ETCO2 during exercise.

Submaximal stress testing can be easily performed in the outpatient setting. In patients being evaluated for pulmonary disease and dyspnea, submaximal stress testing may help detect patients that may benefit from further workup of pulmonary hypertension.
Enhanced anti-tumor activity of dipeptidyl peptidase inhibitor PT-100 in combination with chemotherapy in mice.
Authors: Sharlene Adams, Barry Jones
Journal: Cancer Research (2004)

Proc Amer Assoc Cancer Res, Volume 45, 2004

3820 

The amino boronic dipeptide, Val-boro-Pro (PT-100), competitively inhibits the dipeptidyl peptidase activity of fibroblast activation protein (FAP) and CD26/DPP-IV. We previously observed that PT-100 significantly inhibited growth of established tumors in mouse models, whereas treatment at earlier stages resulted in rejection of tumors derived from fibrosarcoma and lymphoma cell lines. The activity of PT-100 involved rapid up-regulation of cytokines and chemokines in the tumor and draining lymph node tissue followed by a tumor-specific immune response. CD26/DPP-IV was not the essential molecular target because the anti-tumor activity was undiminished in CD26−/− mice. We have found that FAP mRNA was expressed in lymph nodes proximal to solid tumors in mice, and as shown by others, FAP was expressed within in vivo tumors. FAP associated with the tumor stroma is thought to play a role in tissue re-modeling required for tumor growth by digestion of collagen I in extracellular matrix. The increased production of cytokines and chemokines observed in PT-100-treated mice indicates an additional regulatory role for FAP. The mechanism of action suggests that PT-100 is uniquely suited for use in combination with other anti-cancer agents; consequently, we have investigated treatment of established tumors in mice with PT-100 plus various chemotherapeutic agents, including cisplatin, paclitaxel and 5-fluorouracil. The addition of PT-100 was found to enhance the activity of each agent. In this study, the combination of PT-100 with gemcitabine was highly effective, as shown in the [Table][1]. For each dose of gemcitabine, the combination had a significantly ( P ≤ 0.05) greater anti-tumor effect than treatment with either agent alone. Tumors were never rejected in mice treated with PT-100, and rejection frequencies did not exceed 20% with any dose of gemcitabine; however, combination treatment caused rejection in 40–60% of mice by day 25 after tumor inoculation, and relapses were not observed over a further 30 days. Treatment with cisplatin and PT-100 similarly increased rejection frequency from 20% in mice treated with 5 mg/kg cisplatin alone to 50%. Following tumor rejection, mice were specifically immune to rechallenge with WEHI 164 tumor cells. Thus PT-100 could stimulate tumor immunity in mice that received active doses of chemotherapy.



![Figure][2]  [1]: #F1
 [2]: pending:yes
Abstract S3-07: 16 year long-term follow-up of the IBIS-I breast cancer prevention trial
Authors: Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes
Journal: Cancer Research (2015)

Abstract Background: Several randomised clinical trials have shown the benefit of tamoxifen in healthy women to reduce their risk of breast cancer. Here, we report the blinded median 16 year follow-up of the IBIS-I trial to update the long-term prevention of breast cancer with tamoxifen treatment. Methods: 7154 pre- and postmenopausal women were randomised to receive daily 20mg tamoxifen (N=3579) or matching placebo (N=3575) for 5 years. The primary endpoint of this analysis was the occurrence of breast cancer (invasive and ductal carcinoma in situ (DCIS)). Secondary endpoints included overall mortality, other cancers, and breast cancer specific mortality. Cox proportional hazard models were used to assess occurrence of breast cancer and survival. All statistical tests were two-sided. Results: After a median of 16.2 years (IQR 14.4 to 17.7) of follow-up, a total of 589 breast cancers have been reported (tamoxifen: 246 (6.9%) vs. placebo: 343 (9.6%)). Tamoxifen reduced the incidence of all breast cancer overall by 29% (HR=0.71 (0.60-0.83), P&amp;lt;0.0001) (Figure 1). Invasive ER-positive (ER+) breast cancers were reduced by 35% (HR=0.65 (0.53-0.80), P&amp;lt;0.0001) (Figure 1), but no effect was seen for invasive ER-negative (ER-) breast cancers (HR=1.06 (0.71-1.58), P=0.8). A non-significant 30% reduction in DCIS was seen with tamoxifen (36 vs. 51, HR=0.70 (0.46-1.07); P=0.1). The overall risk reduction was similar in years 0-10 (HR=0.71) and years 10-20 (HR=0.70). Similar effects were seen in pre- and postmenopausal women (HR 0.71 vs. 0.71). All-cause mortality was non-significantly increased in women randomised to tamoxifen (173 vs. 158, OR=1.10 (0.88-1.38), P=0.4). The excess in deaths with tamoxifen is smaller than in the 96 month update. No differences in breast cancer mortality was seen (24 tamoxifen vs. 27 placebo; OR=0.89 (0.49-1.60), P=0.7). A non-significant increase in other cancers than breast were reported by women on tamoxifen (350 vs. 315, OR=1.12 (0.95-1.32); P=0.2). Specifically more endometrial cancers (28 vs. 17), non-melanoma skin cancers (108 vs. 85), and lung cancer (32 vs. 20) were found in those randomised to tamoxifen. Conclusion: This updated analysis of the IBIS-I trial confirms the significant reduction in breast cancer occurrence with tamoxifen in the post-treatment follow-up period. These results indicate tamoxifen has a long-term preventive effect on invasive ER+ breast cancer in both pre- and postmenopausal women. Citation Format: Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes. 16 year long-term follow-up of the IBIS-I breast cancer prevention trial [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S3-07.
Performance of Current Guidelines for Diagnosis of Macrophage Activation Syndrome Complicating Systemic Juvenile Idiopathic Arthritis
Authors: Sergio Davì, Francesca Minoia, Angela Pistorio, AnnaCarin Horne, Alessandro Consolaro, Silvia Rosina, Francesca Bovis, Rolando Cimaz, Maria Luz Gamir, Norman T. Ilowite, Isabelle Kone‐Paut, Sheila Knupp Feitosa de Oliveira, Deborah McCurdy, Clovis Artur Silva, Flavio Sztajnbok, Elena Tsitsami, Erbil Unsal, Jennifer E. Weiss, Nico Wulffraat, Mario Abinun, Amita Aggarwal, Maria Teresa Apaz, Itziar Astigarraga, Fabrizia Corona, Ruben Cuttica, Gianfranco D'Angelo, Eli M. Eisenstein, Soad Hashad, Loredana Lepore, Velma Mulaosmanovic, Susan Nielsen, Sampath Prahalad, Donato Rigante, Valda Stanevicha, Gary Sterba, Gordana Susic, Syuji Takei, Ralf Trauzeddel, Mabruka Zletni, Nicolino Ruperto, Alberto Martini, Randy Q. Cron, Angelo Ravelli
Journal: Arthritis & Rheumatology (2014)

Objective To compare the capacity of the 2004 diagnostic guidelines for hemophagocytic lymphohistiocytosis (HLH‐2004) with the capacity of the preliminary diagnostic guidelines for systemic juvenile idiopathic arthritis (JIA)–associated macrophage activation syndrome (MAS) to discriminate MAS complicating systemic JIA from 2 potentially confusable conditions, represented by active systemic JIA without MAS and systemic infection. Methods International pediatric rheumatologists and hemato‐oncologists were asked to retrospectively collect clinical information from patients with systemic JIA–associated MAS and confusable conditions. The ability of the guidelines to differentiate MAS from the control diseases was evaluated by calculating the sensitivity and specificity of each set of guidelines and the kappa statistics for concordance with the physician's diagnosis. Owing to the fact that not all patients were assessed for hemophagocytosis on bone marrow aspirates and given the lack of data on natural killer cell activity and soluble CD25 levels, the HLH‐2004 guidelines were adapted to enable the diagnosis of MAS when 3 of 5 of the remaining items (3/5‐adapted) or 4 of 5 of the remaining items (4/5‐adapted) were present. Results The study sample included 362 patients with systemic JIA and MAS, 404 patients with active systemic JIA without MAS, and 345 patients with systemic infection. The best capacity to differentiate MAS from systemic JIA without MAS was found when the preliminary MAS guidelines were applied. The 3/5‐adapted HLH‐2004 guidelines performed better than the 4/5‐adapted guidelines in distinguishing MAS from active systemic JIA without MAS. The 3/5‐adapted HLH‐2004 guidelines and the preliminary MAS guidelines with the addition of ferritin levels ≥500 ng/ml discriminated best between MAS and systemic infections. Conclusion The preliminary MAS guidelines showed the strongest ability to identify MAS in systemic JIA. The addition of hyperferritinemia enhanced their capacity to differentiate MAS from systemic infections. The HLH‐2004 guidelines are likely not appropriate for identification of MAS in children with systemic JIA.